Revenue Growth
Q3 2025 revenue increased by 22% year over year, marking the fifth consecutive quarter of double-digit growth.
Successful Milestones Achieved
Achieved FDA indication expansion to functional abdominal pain and functional dyspepsia with associated nausea symptoms for both children and adults.
Strong Payer Engagement
Engagement with major payers is deemed comprehensive, with a focus on policy coverage expansion for pediatric use.
Positive Gross Margin
Gross margin for 2025 was 83.3%, showing resilience despite some declines from previous years.
Strategic Commercial Plan for 2026
Plans for broad adoption of IV Stem with new Category One CPT code effective January 1, 2026, promising improved reimbursement and adoption.
Cash Position Improved
Cash on hand was $4,400,000 as of September 2025, improved by an additional $2,800,000 raised in October 2025.